Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study

Table 3 Inferential analysis HFMSE

	Value	SE	DF	t-value	p-value
(Intercept)	1.386	0.697	833	1.987	0.05
Baseline_m14 versus m14_m26	0.659	0.366	833	1.797	0.07
Baseline_m14 versus m26_m38	0.550	0.608	833	0.905	0.37
Age at symptom onset	0.014	0.028	170	0.492	0.62
Baseline score	− 0.044	0.021	170	− 2.119	0.04
*SMN2* copy number	1.785	0.624	170	2.861	0.005
Age at start of treatment	− 0.009	0.005	170	− 1.667	0.1
Gender (m)	0.704	0.460	170	1.528	0.13
Loss of sitting before start of treatment	0.170	0.742	170	0.229	0.82
Loss of walking before start of treatment	0.335	0.741	170	0.452	0.65

Inferential analysis evaluates the effect of age at diagnosis, age at start of treatment, SMN2 copy number (≤ 3 SMN2 copies vs. ≥ 4 SMN2 copies), gender, baseline HFMSE score, and past time from baseline on changes in HFMSE score
SE Standard error, DF degree of freedom

ISSN: 1750-1172